{
    "hands_on_practices": [
        {
            "introduction": "Chronic Myeloid Leukemia often begins with a single hematopoietic progenitor cell that acquires the BCR-ABL1 fusion gene. This practice uses a foundational mathematical model from population genetics to estimate how long it takes for this single cell to expand and dominate its local microenvironment. By working through this exercise , you will gain a quantitative understanding of clonal selection and the concept of clinical latency, which explains the long, asymptomatic period before diagnosis.",
            "id": "4318369",
            "problem": "A single hematopoietic progenitor acquires the Breakpoint Cluster Region–ABL1 (BCR-ABL1) fusion in the bone marrow of a person who later develops Chronic Myeloid Leukemia (CML). Consider an effective local niche of actively cycling myeloid progenitors of size $N$, where $N$ represents the number of competitor cells sharing the same proliferative microenvironment. Let $M(t)$ denote the number of BCR-ABL1–positive cells and $W(t)$ denote the number of BCR-ABL1–negative competitor cells at time $t$ (in years). Assume continuous-time exponential dynamics grounded in the standard birth–death approximation for well-mixed populations: the BCR-ABL1 clone has a net Malthusian growth parameter advantage $s$ over background, such that the wild-type population grows with parameter $r$ and the BCR-ABL1 population grows with parameter $r+s$, where $s>0$ reflects the aggregate increase in proliferation and/or survival due to constitutive tyrosine kinase signaling. At $t=0$, a single BCR-ABL1–positive cell appears in the niche, so $M(0)=1$, and the remaining $N-1$ cells are wild-type, so $W(0)=N-1$.\n\nStarting only from these assumptions and definitions, derive an analytic expression for the time $t^{\\ast}$ at which the BCR-ABL1 clone reaches clonal dominance in the niche, defined here as $M(t^{\\ast})=W(t^{\\ast})$. Then, evaluate $t^{\\ast}$ for $N=3000$ and $s=1.2$ per year. Round your numerical answer to three significant figures and express it in years. Finally, briefly interpret how this time scale relates to clinical latency from the initial genomic event to detectable disease by quantitative polymerase chain reaction (qPCR) in precision diagnostics, noting that this interpretive step should not alter your computed numerical answer.",
            "solution": "The problem asks for the derivation of an analytic expression for the time $t^{\\ast}$ at which a BCR-ABL1–positive clonal population, $M(t)$, achieves dominance over a wild-type competitor population, $W(t)$, within a shared niche of initial size $N$. It also asks for a numerical evaluation of this time and a brief interpretation.\n\nFirst, we establish the mathematical model based on the provided information. The populations are governed by continuous-time exponential growth dynamics. The number of BCR-ABL1–positive cells, $M(t)$, grows with a net Malthusian parameter of $r+s$, while the number of wild-type competitor cells, $W(t)$, grows with a parameter of $r$. Here, $s > 0$ represents the selective growth advantage of the mutant clone. The corresponding differential equations are:\n$$ \\frac{dM}{dt} = (r+s)M(t) $$\n$$ \\frac{dW}{dt} = rW(t) $$\n\nThese are first-order linear ordinary differential equations. Their solutions are exponential functions of time:\n$$ M(t) = M(0) \\exp((r+s)t) $$\n$$ W(t) = W(0) \\exp(rt) $$\n\nThe problem provides the initial conditions at $t=0$. A single BCR-ABL1–positive cell appears, so $M(0)=1$. The niche initially contains $N$ cells in total, with the remainder being wild-type, so $W(0)=N-1$. Substituting these initial conditions into the general solutions yields the specific dynamics for this system:\n$$ M(t) = 1 \\cdot \\exp((r+s)t) = \\exp((r+s)t) $$\n$$ W(t) = (N-1) \\exp(rt) $$\n\nThe problem defines clonal dominance as the time point $t^{\\ast}$ where the number of mutant cells equals the number of wild-type cells, i.e., $M(t^{\\ast}) = W(t^{\\ast})$. We set the two expressions equal to find this time:\n$$ \\exp((r+s)t^{\\ast}) = (N-1) \\exp(rt^{\\ast}) $$\n\nTo solve for $t^{\\ast}$, we can simplify this equation. Using the property of exponents $\\exp(a+b) = \\exp(a)\\exp(b)$, we can rewrite the left-hand side:\n$$ \\exp(rt^{\\ast}) \\exp(st^{\\ast}) = (N-1) \\exp(rt^{\\ast}) $$\n\nSince $\\exp(rt^{\\ast})$ is strictly positive for any finite $r$ and $t^{\\ast}$, we can divide both sides by this term. This step reveals that the time to dominance is independent of the background growth rate $r$.\n$$ \\exp(st^{\\ast}) = N-1 $$\n\nTo isolate $t^{\\ast}$, we take the natural logarithm, denoted as $\\ln$, of both sides of the equation:\n$$ \\ln(\\exp(st^{\\ast})) = \\ln(N-1) $$\n$$ st^{\\ast} = \\ln(N-1) $$\n\nFinally, we solve for $t^{\\ast}$ to obtain the desired analytic expression:\n$$ t^{\\ast} = \\frac{\\ln(N-1)}{s} $$\n\nNext, we evaluate this expression using the provided numerical values: $N=3000$ and $s=1.2$ per year.\n$$ t^{\\ast} = \\frac{\\ln(3000-1)}{1.2} = \\frac{\\ln(2999)}{1.2} $$\n\nUsing a calculator for the numerical value:\n$$ t^{\\ast} \\approx \\frac{8.006034}{1.2} \\approx 6.671695 \\text{ years} $$\n\nThe problem requires rounding the final answer to three significant figures.\n$$ t^{\\ast} \\approx 6.67 \\text{ years} $$\n\nFinally, for the interpretation, the calculated time $t^{\\ast} \\approx 6.67$ years represents the duration required for a single neoplastic cell to expand to a population size equal to that of its direct competitors within its local microenvironment or niche. This is a model of the pre-clinical latency period, the silent phase of clonal evolution following the initiating oncogenic event. At time $t^{\\ast}$, the number of BCR-ABL1 cells is $M(t^{\\ast}) = N-1 = 2999$. This cell count is far below the threshold for systemic disease detection by standard clinical methods like quantitative polymerase chain reaction (qPCR), which typically require a much larger total tumor burden (e.g., > $10^5$ to $10^6$ cells). Therefore, this calculated time scale represents only a fraction of the total time from the initial mutation to clinical diagnosis. The full clinical latency would also include the subsequent time required for the clone to grow from this state of local dominance to a macroscopically detectable, systemic disease burden, potentially involving dissemination to and colonization of other niches. The result is nonetheless biologically plausible, as CML is known to have a long latency period.",
            "answer": "$$ \\boxed{6.67} $$"
        },
        {
            "introduction": "Once a patient's clinical signs suggest Chronic Myeloid Leukemia, a definitive diagnosis is crucial, often relying on tests like Fluorescence In Situ Hybridization (FISH) to detect the BCR-ABL1 fusion. This practice applies the fundamental principles of Bayesian inference to interpret the results of such a diagnostic test. By calculating the post-test probability of disease , you will learn how to formally update clinical suspicion based on laboratory evidence, a core skill in evidence-based medicine and genomic diagnostics.",
            "id": "4318394",
            "problem": "A patient with clinical features and complete blood count suggestive of Chronic Myeloid Leukemia (CML) undergoes Fluorescence In Situ Hybridization (FISH) targeting the breakpoint cluster region-Abelson (BCR-ABL) fusion. Let $D$ denote the event that the BCR-ABL fusion is truly present in the patient’s leukemic cells, and let $T^{+}$ denote the event that the FISH assay returns a positive result.\n\nAssume the following well-tested diagnostic characteristics of the FISH assay: sensitivity is $0.95$ and specificity is $0.98$. The pretest probability (prior probability) that the patient harbors the BCR-ABL fusion based on clinical assessments is $0.70$. The FISH test returns a positive result.\n\nStarting from the fundamental definition of conditional probability and the law of total probability, derive an expression for the posttest probability $P(D \\mid T^{+})$ in terms of $P(T^{+} \\mid D)$, $P(T^{+} \\mid \\overline{D})$, and $P(D)$, and then calculate its value using the provided assay parameters. Express the final probability as a decimal, rounded to four significant figures, and do not use a percentage sign.",
            "solution": "The problem is subjected to validation before a solution is attempted.\n\n### Step 1: Extract Givens\n- $D$: The event that the BCR-ABL fusion is truly present.\n- $T^{+}$: The event that the FISH assay returns a positive result.\n- Sensitivity of the FISH assay: $P(T^{+} \\mid D) = 0.95$.\n- Specificity of the FISH assay: $0.98$.\n- Pretest probability (prior probability): $P(D) = 0.70$.\n- The observed event is a positive test result, $T^{+}$.\n- The objective is to derive an expression for the posttest probability $P(D \\mid T^{+})$ and calculate its numerical value.\n\n### Step 2: Validate Using Extracted Givens\nThe problem is evaluated against the established criteria:\n- **Scientifically Grounded**: The problem is grounded in the principles of molecular diagnostics and probability theory. Chronic Myeloid Leukemia (CML) is defined by the presence of the BCR-ABL fusion gene. Fluorescence In Situ Hybridization (FISH) is a standard cytogenetic technique used to detect this fusion. The concepts of sensitivity, specificity, and pretest/posttest probabilities (Bayesian inference) are fundamental to evaluating diagnostic tests. The numerical values provided are realistic for a high-performance assay applied to a patient population with strong clinical indicators for the disease.\n- **Well-Posed**: The problem provides all necessary information to determine a unique solution. It clearly defines the events, provides the required conditional and prior probabilities, and states the quantity to be calculated.\n- **Objective**: The problem is stated in precise, objective language, free of ambiguity or subjective claims. It is a formal problem in applied probability.\n\nThe problem does not exhibit any of the listed flaws (e.g., scientific unsoundness, incompleteness, contradiction, infeasibility). It is a standard, well-posed problem in biostatistics and medical diagnostics.\n\n### Step 3: Verdict and Action\nThe problem is valid. A solution will be provided.\n\n### Derivation and Calculation\nThe objective is to calculate the posttest probability of the disease, $P(D \\mid T^{+})$, which is the probability that the patient truly has the BCR-ABL fusion given that the FISH assay returned a positive result. The derivation will begin from the fundamental definition of conditional probability.\n\nBy definition, the conditional probability of event $D$ given event $T^{+}$ is:\n$$P(D \\mid T^{+}) = \\frac{P(D \\cap T^{+})}{P(T^{+})}$$\nwhere $P(D \\cap T^{+})$ is the joint probability of both events occurring.\n\nThe numerator, $P(D \\cap T^{+})$, can be re-expressed using the definition of conditional probability for $P(T^{+} \\mid D)$:\n$$P(T^{+} \\mid D) = \\frac{P(D \\cap T^{+})}{P(D)}$$\nRearranging this gives:\n$$P(D \\cap T^{+}) = P(T^{+} \\mid D) P(D)$$\n\nThe denominator, $P(T^{+})$, is the total probability of obtaining a positive test result. This can be calculated using the Law of Total Probability. A positive result can occur in two mutually exclusive scenarios: the patient has the disease and tests positive ($D \\cap T^{+}$), or the patient does not have the disease and tests positive ($\\overline{D} \\cap T^{+}$), where $\\overline{D}$ is the complement of $D$ (the patient does not have the fusion).\n$$P(T^{+}) = P(D \\cap T^{+}) + P(\\overline{D} \\cap T^{+})$$\nApplying the definition of conditional probability to each term on the right-hand side:\n$$P(T^{+}) = P(T^{+} \\mid D) P(D) + P(T^{+} \\mid \\overline{D}) P(\\overline{D})$$\n\nSubstituting the expanded expressions for the numerator and the denominator back into the original equation for $P(D \\mid T^{+})$ yields Bayes' theorem:\n$$P(D \\mid T^{+}) = \\frac{P(T^{+} \\mid D) P(D)}{P(T^{+} \\mid D) P(D) + P(T^{+} \\mid \\overline{D}) P(\\overline{D})}$$\nThis is the required expression for the posttest probability in terms of the prior probability $P(D)$ and the conditional probabilities of the test results.\n\nWe are given the following values:\n- The prior probability of disease, $P(D) = 0.70$.\n- The sensitivity of the test, $P(T^{+} \\mid D) = 0.95$.\n- The specificity of the test, which is $P(T^{-} \\mid \\overline{D}) = 0.98$, where $T^{-}$ is a negative test result.\n\nFrom the givens, we can deduce the remaining probabilities needed for the calculation:\n- The prior probability of not having the disease is $P(\\overline{D}) = 1 - P(D) = 1 - 0.70 = 0.30$.\n- The probability of a positive test in a disease-free individual, $P(T^{+} \\mid \\overline{D})$, is the complement of the specificity. This is because, for a disease-free individual, the test must be either positive or negative. Thus, $P(T^{+} \\mid \\overline{D}) + P(T^{-} \\mid \\overline{D}) = 1$.\n$$P(T^{+} \\mid \\overline{D}) = 1 - P(T^{-} \\mid \\overline{D}) = 1 - \\text{specificity} = 1 - 0.98 = 0.02$$\nThis term, $P(T^{+} \\mid \\overline{D})$, is also known as the false positive rate.\n\nNow, we substitute these numerical values into the derived expression for $P(D \\mid T^{+})$:\n$$P(D \\mid T^{+}) = \\frac{(0.95)(0.70)}{(0.95)(0.70) + (0.02)(0.30)}$$\nFirst, calculate the numerator and the terms in the denominator:\n- Numerator: $P(T^{+} \\mid D) P(D) = 0.95 \\times 0.70 = 0.665$. This is the probability of a true positive result in the study population.\n- Denominator Term 1: This is the same as the numerator, $0.665$.\n- Denominator Term 2: $P(T^{+} \\mid \\overline{D}) P(\\overline{D}) = 0.02 \\times 0.30 = 0.006$. This is the probability of a false positive result in the study population.\n\nThe total probability of a positive test, $P(T^{+})$, is the sum of these two terms:\n$$P(T^{+}) = 0.665 + 0.006 = 0.671$$\n\nFinally, the posttest probability is:\n$$P(D \\mid T^{+}) = \\frac{0.665}{0.671}$$\nPerforming the division:\n$$P(D \\mid T^{+}) \\approx 0.9910581222...$$\nRounding to four significant figures as required by the problem statement, we obtain:\n$$P(D \\mid T^{+}) \\approx 0.9911$$",
            "answer": "$$\\boxed{0.9911}$$"
        },
        {
            "introduction": "The ultimate goal of modern CML therapy is to achieve a deep molecular response (DMR), potentially allowing patients to stop treatment safely. This advanced practice delves into the statistical complexities of monitoring for DMR, where the BCR-ABL1 transcript levels are near the limit of detection and assay variability is a significant challenge. This exercise  will guide you through evaluating and designing robust laboratory protocols to minimize the risk of misclassifying a patient's response, a critical aspect of precision monitoring.",
            "id": "4318371",
            "problem": "A molecular diagnostics laboratory quantifies Breakpoint Cluster Region-Abelson 1 (BCR-ABL1) transcripts in chronic myeloid leukemia on the International Scale (IS) using Reverse Transcription quantitative Polymerase Chain Reaction (RT-qPCR). On the IS, major molecular response categories are defined by transcript ratio thresholds: MR4 corresponds to BCR-ABL1/control gene $\\le 0.01\\%$, and MR4.5 corresponds to $\\le 0.0032\\%$. At low transcript levels, multiplicative sources of error from reverse transcription efficiency, amplification efficiency, and calibrator uncertainty make the $\\log_{10}$-transformed IS ratio approximately Gaussian across technical replicates. Assume the following foundational model and facts:\n- The $\\log_{10}$ of the measured IS ratio, $Y$, for a single technical replicate is distributed as $Y \\sim \\mathcal{N}(\\mu, \\sigma^{2})$ with replicate-to-replicate independence for a given extract. Here $\\mu$ is the true $\\log_{10}$ IS ratio and $\\sigma$ summarizes assay variability from extraction through RT-qPCR. In well-calibrated laboratories at low IS levels, a typical per-replicate $\\sigma$ is about $0.12$ $\\log_{10}$-units.\n- For classification, the laboratory compares $Y$ to fixed $\\log_{10}$ thresholds $t_4$ and $t_{4.5}$ corresponding to MR4 and MR4.5 on the IS, respectively. Equivalently, comparing the untransformed IS value to $0.01\\%$ (MR4) and $0.0032\\%$ (MR4.5).\n- Independent technical replicates can be used to reduce decision error, and independent biological confirmation on a subsequent blood draw reduces the chance of a transient or stochastic false categorization.\n\nConsider a patient whose true IS ratio is $0.005\\%$, which is below the MR4 threshold but above the MR4.5 threshold. Let $\\mu = \\log_{10}(0.00005)$, $t_{4.5} = \\log_{10}(0.000032)$, and per-replicate $\\sigma = 0.12$. Using only the normality assumption on $\\log_{10}$-IS and independence across technical replicates, reason from first principles to quantify how assay variability near the MR4.5 boundary impacts misclassification and how replication rules can control it. Then, select the decision rule that simultaneously satisfies all of the following three criteria:\n- Keeps the probability of a false MR4.5 call on a single visit at or below $5\\%$ for the patient with true IS $0.005\\%$.\n- Achieves at least $50\\%$ probability of correctly calling MR4.5 on a single visit when the true IS equals the MR4.5 threshold (i.e., $\\mu = t_{4.5}$).\n- Includes an explicit, independent confirmation step on a subsequent sample to support durable classification at MR4.5.\n\nWhich option best meets these criteria while reflecting sound laboratory practice on the International Scale?\n\nA. Call MR4.5 on a single technical replicate if its IS is below $0.0032\\%$ or undetectable with adequate control gene input; no confirmation required if internal controls pass.\n\nB. Perform $2$ technical replicates on one sample; call MR4.5 only if both replicates are below $0.0032\\%$; confirm within $4$ weeks on a new blood draw requiring any single replicate below $0.0032\\%$.\n\nC. Perform $3$ technical replicates on one sample; call MR4.5 if at least $2$ of $3$ replicates are below $0.0032\\%$; confirm within $4$–$12$ weeks on an independent sample meeting the same $2$ of $3$ rule and adequate control gene copy criteria.\n\nD. Perform $2$ technical replicates; compute the average of the two $\\log_{10}$-IS values and call MR4.5 if this average is below $\\log_{10}(0.000032)$; no further confirmation is necessary if the control gene copy number exceeds prespecified acceptance thresholds.",
            "solution": "The problem requires the evaluation of four different decision rules for classifying a patient as having achieved Major Molecular Response 4.5 (MR4.5) in chronic myeloid leukemia (CML) monitoring. The evaluation is based on three specific criteria related to statistical error rates and laboratory practice.\n\nFirst, we formalize the problem. Let $R$ be the measured IS ratio. The problem states that $Y = \\log_{10}(R)$ is a normally distributed random variable, $Y \\sim \\mathcal{N}(\\mu, \\sigma^2)$, where $\\mu$ is the true log$_{10}$-transformed IS ratio and $\\sigma$ is the standard deviation of the measurement on the $\\log_{10}$ scale.\nThe given parameters are:\n- Standard deviation per replicate: $\\sigma = 0.12$.\n- The MR4.5 threshold is a ratio of $0.0032\\%$, which is $0.000032$.\n- The corresponding threshold on the $\\log_{10}$ scale is $t_{4.5} = \\log_{10}(0.000032) = \\log_{10}(3.2 \\times 10^{-5}) \\approx -4.49485$.\n\nA decision rule makes a call of MR4.5. We must evaluate each proposed rule against three criteria.\n\n### Criterion 1: False Positive Rate\nThe probability of a false MR4.5 call must be at or below $5\\%$ ($\\le 0.05$) for a patient whose true IS ratio is $0.005\\%$, which is $0.00005$.\nFor this patient, the true mean of the log-ratio is $\\mu_1 = \\log_{10}(0.00005) = \\log_{10}(5 \\times 10^{-5}) \\approx -4.30103$.\nLet's calculate the probability, $p_1$, that a single replicate from this patient falls below the MR4.5 threshold:\n$$ p_1 = P(Y < t_{4.5} \\mid \\mu = \\mu_1) $$\nTo calculate this, we standardize the variable. Let $Z \\sim \\mathcal{N}(0, 1)$ be the standard normal variable.\n$$ p_1 = P\\left( \\frac{Y - \\mu_1}{\\sigma} < \\frac{t_{4.5} - \\mu_1}{\\sigma} \\right) = P\\left( Z < \\frac{-4.49485 - (-4.30103)}{0.12} \\right) $$\n$$ p_1 = P\\left( Z < \\frac{-0.19382}{0.12} \\right) \\approx P(Z < -1.615) $$\nUsing a standard normal distribution cumulative density function, $\\Phi(-1.615) \\approx 0.0531$.\nSo, for any single replicate, the probability of it being below the threshold is $p_1 \\approx 5.31\\%$.\n\n### Criterion 2: Statistical Power (Sensitivity)\nThe probability of a correct MR4.5 call must be at least $50\\%$ ($\\ge 0.50$) when the patient's true IS ratio is exactly at the threshold, i.e., $0.0032\\%$.\nFor this scenario, the true mean of the log-ratio is $\\mu_2 = t_{4.5} \\approx -4.49485$.\nLet's calculate the probability, $p_2$, that a single replicate from this patient falls below the MR4.5 threshold:\n$$ p_2 = P(Y < t_{4.5} \\mid \\mu = t_{4.5}) $$\n$$ p_2 = P\\left( \\frac{Y - t_{4.5}}{\\sigma} < \\frac{t_{4.5} - t_{4.5}}{\\sigma} \\right) = P(Z < 0) = 0.5 $$\nSo, for any single replicate from a patient whose true value is at the threshold, the probability of it being below the threshold is exactly $p_2 = 50\\%$.\n\n### Criterion 3: Confirmation\nThe decision rule must include an explicit, independent confirmation step on a subsequent sample.\n\nNow, we evaluate each option based on its performance on a single visit for the first two criteria and its inclusion of the third.\n\n**Option A: Call MR4.5 on a single technical replicate if its IS is below $0.0032\\%$. No confirmation required.**\n- **Criterion 1 (False Positive $\\le 5\\%$):** The probability of a false call is the probability that a single replicate is below the threshold, which is $p_1 \\approx 0.0531$ or $5.31\\%$. Since $5.31\\% > 5\\%$, this criterion is **not met**.\n- **Criterion 2 (Power $\\ge 50\\%$):** The probability of a correct call is the probability that a single replicate is below the threshold, which is $p_2 = 0.5$ or $50\\%$. This criterion is **met**.\n- **Criterion 3 (Confirmation):** The rule explicitly states \"no confirmation required\". This criterion is **not met**.\n**Verdict for A:** Incorrect.\n\n**Option B: Perform $2$ technical replicates; call MR4.5 only if both are below $0.0032\\%$. Confirmation required.**\n- **Criterion 1 (False Positive $\\le 5\\%$):** Let $Y_1, Y_2$ be the results of two independent replicates. A false call occurs if $Y_1 < t_{4.5}$ AND $Y_2 < t_{4.5}$. The probability is $p_1 \\times p_1 = p_1^2$.\n$P(\\text{False Call}) = (0.0531)^2 \\approx 0.00282$, or $0.282\\%$. Since $0.282\\% \\le 5\\%$, this criterion is **met**.\n- **Criterion 2 (Power $\\ge 50\\%$):** A correct call occurs if $Y_1 < t_{4.5}$ AND $Y_2 < t_{4.5}$ for a patient with $\\mu = t_{4.5}$. The probability is $p_2 \\times p_2 = p_2^2$.\n$P(\\text{Correct Call}) = (0.5)^2 = 0.25$, or $25\\%$. Since $25\\% < 50\\%$, this criterion is **not met**.\n- **Criterion 3 (Confirmation):** The rule includes a confirmation step. This criterion is **met**.\n**Verdict for B:** Incorrect.\n\n**Option C: Perform $3$ technical replicates; call MR4.5 if at least $2$ of $3$ are below $0.0032\\%$. Confirmation required.**\n- **Rule:** This follows a binomial distribution. Let $X$ be the number of replicates below the threshold out of $n=3$ trials. The probability of a call is $P(X \\ge 2) = P(X=2) + P(X=3)$.\nUsing the binomial probability formula $P(X=k) = \\binom{n}{k}p^k(1-p)^{n-k}$:\n$$P(X \\ge 2) = \\binom{3}{2}p^2(1-p)^1 + \\binom{3}{3}p^3(1-p)^0 = 3p^2(1-p) + p^3$$\n- **Criterion 1 (False Positive $\\le 5\\%$):** We use $p = p_1 \\approx 0.0531$.\n$P(\\text{False Call}) = 3(0.0531)^2(1-0.0531) + (0.0531)^3$\n$P(\\text{False Call}) \\approx 3(0.00282)(0.9469) + 0.00015 \\approx 0.00801 + 0.00015 = 0.00816$.\nThis probability is $0.816\\%$, which is well below $5\\%$. This criterion is **met**.\n- **Criterion 2 (Power $\\ge 50\\%$):** We use $p = p_2 = 0.5$.\n$P(\\text{Correct Call}) = 3(0.5)^2(1-0.5) + (0.5)^3 = 3(0.25)(0.5) + 0.125 = 0.375 + 0.125 = 0.5$.\nThe probability is $50\\%$. Since $50\\% \\ge 50\\%$, this criterion is **met**.\n- **Criterion 3 (Confirmation):** The rule explicitly includes confirmation on an independent sample. This criterion is **met**.\n**Verdict for C:** Correct.\n\n**Option D: Perform $2$ technical replicates; average the $\\log_{10}$-IS values and call MR4.5 if the average is below $\\log_{10}(0.000032)$. No confirmation necessary.**\n- **Rule:** Let $\\bar{Y} = (Y_1+Y_2)/2$. The mean of $\\bar{Y}$ is $\\mu$ and its variance is $\\sigma^2/2$. So the standard deviation of $\\bar{Y}$ is $\\sigma_{\\bar{Y}} = \\sigma/\\sqrt{2} \\approx 0.08485$.\n- **Criterion 1 (False Positive $\\le 5\\%$):** We test $P(\\bar{Y} < t_{4.5})$ for $\\mu = \\mu_1 \\approx -4.30103$.\n$P(\\text{False Call}) = P\\left( Z < \\frac{t_{4.5} - \\mu_1}{\\sigma_{\\bar{Y}}} \\right) = P\\left( Z < \\frac{-4.49485 - (-4.30103)}{0.08485} \\right)$\n$P(\\text{False Call}) \\approx P\\left( Z < \\frac{-0.19382}{0.08485} \\right) \\approx P(Z < -2.284)$.\n$\\Phi(-2.284) \\approx 0.0112$. This probability is $1.12\\%$, which is below $5\\%$. This criterion is **met**.\n- **Criterion 2 (Power $\\ge 50\\%$):** We test $P(\\bar{Y} < t_{4.5})$ for $\\mu = \\mu_2 = t_{4.5}$.\n$P(\\text{Correct Call}) = P\\left( Z < \\frac{t_{4.5} - t_{4.5}}{\\sigma_{\\bar{Y}}} \\right) = P(Z < 0) = 0.5$.\nThe probability is $50\\%$. This criterion is **met**.\n- **Criterion 3 (Confirmation):** The rule states \"no further confirmation is necessary\". This criterion is **not met**.\n**Verdict for D:** Incorrect.\n\nIn summary, only Option C satisfies all three required criteria. It provides a low false positive rate for a patient just outside the MR4.5 response category, sufficient power to detect a patient who is truly at the boundary, and incorporates the sound laboratory practice of confirming a significant clinical finding on a new biological sample.",
            "answer": "$$\\boxed{C}$$"
        }
    ]
}